Issue Date: November 28, 2016
Celgene acquires a myeloma treatment
Celgene has acquired the proteasome inhibitor marizomib from Triphase Accelerator for an undisclosed sum plus future milestone payments. Triphase has completed Phase I clinical trials of marizomib as a treatment for glioblastoma and multiple myeloma. Celgene already markets the multiple myeloma treatments Revlimid and Thalomid. Triphase, a spin-off from the Ontario Institute for Cancer Research, granted Celgene the option to buy the drug in 2014.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society